title: [Dual regulation effect of somatostatin on immunity in patients with severe sepsis caused by abdominal diseases].
abstract: OBJECTIVE
  to investigate the effect of somatostatin on inflammatory immune disorders and prognosis in patients with severe sepsis caused by abdominal diseases.
  
  
  METHODS
  fifty-three patients with severe abdominal sepsis (age > 18 years, APACHE-II score > 15) from June 2005 to June 2009 were randomly divided into Somatostatin group (n = 23) and SSC Group (n = 30). Fifteen healthy volunteers of the same age range were chosen as Control group. The SSC group was treated with classical SSC therapy, and the Somatostatin Group was treated with the same regime plus 14-peptide somatostatin continuous infusion at the dose of 6 mg/24 h for 7 days. The serum levels of interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α) were determined by using ELISA. CD(4)(+), CD(8)(+) T cell subsets were determined by fluorescence activated cell sorter(FACS) and CD(4)(+)/CD(8)(+) was calculated. APACHE-II score was observed on admission (d1) and day 3, 7 and 14 after treatment. Morality rates in 28 days in two groups were recorded.
  
  
  RESULTS
  compared with Control group, IL-10 and TNF-α levels were significantly elevated in patients with severe abdominal sepsis (P < 0.05), while CD(4)(+), CD(8)(+) T cell and CD(4)(+)/CD(8)(+) decreased significantly (P < 0.05). Compared with the Somatostatin group CD(4)(+), CD(8)(+) T cell and CD(4)(+)/CD(8)(+) on d7 and d14 in SSC Group were significantly increased (P < 0.05), while IL-10 and TNF-α decreased significantly(P < 0.05). APACHE-II scores on d3, d7, d14 of Somatostatin group were significantly lower than those of SSC group, and 28 d mortality rate also declined.
  
  
  CONCLUSIONS
  in patients with severe abdominal sepsis, systemic inflammatory response and immune suppression exist simultaneously. Somatostatin has a dual immunomodulatory activity in these patients.
authors.affiliation: Department of Hepatobiliary Surgery, First Affiliated Hospital of Huzhou Normal School, Huzhou 313000, China. d_fengwm@sina.com
authors.forename: Wen-Ming
authors.initials: WM
authors.lastname: Feng
authors.forename: Ying
authors.initials: Y
authors.lastname: Bao
authors.forename: Mao-Yun
authors.initials: MY
authors.lastname: Fei
authors.forename: Cheng-Wu
authors.initials: CW
authors.lastname: Tang
authors.forename: Yao
authors.initials: Y
authors.lastname: Wang
authors.forename: Zhen-Zhong
authors.initials: ZZ
authors.lastname: Chai
authors.forename: Lian-Jin
authors.initials: LJ
authors.lastname: Qin
authors.forename: San-Xiong
authors.initials: SX
authors.lastname: Huang
mesh_terms: D018806:APACHE; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000097:blood; D008297:Male; D011379:Prognosis; D011446:Prospective Studies; D018805:Sepsis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology*; D013004:Somatostatin / Q000627:therapeutic use*; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: C508609:IL10 protein, human; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D013004:Somatostatin